Severe LH Suppressed Patients After Administration of a GnRH Antagonist (OPTOMALH)
Infertility, Female Infertility, Male Infertility
About this trial
This is an interventional treatment trial for Infertility, Female Infertility, Male Infertility focused on measuring Infertility, IVF, ovarian stimulation, rec LH, GnRH antagonist
Eligibility Criteria
Inclusion Criteria:
1. The patient is eligible for IVF and will be treated according to the Summary of Product Characteristics (SmPC) and routine practice in participating centres.
2. The patient must be willing and able to comply with the protocol for the duration of the study.
3. The patient has given written informed consent with the understanding that the consent may be withdrawn by her at any time without prejudice for her future medical care.
4. Must be hyper-responder to antagonist according definition
Exclusion Criteria:
- Ovarian, uterine or mammary cancer.
- Tumours of the hypothalamus and pituitary gland.
- Uterine myoma requiring treatment.
- Ovarian enlargement or cyst of unknown aetiology.
- A clinically significant systemic disease.
- Abnormal gynaecological bleeding of undetermined origin.
- Known allergy or hypersensitivity to human gonadotrophin preparations.
- Entered previously into this study or simultaneous participation in another clinical study.
- Age > 39 yrs,
- BMI > 32 kg/m2,
- Patient with no cycles: PCOS or an anovulatory patient. -
Sites / Locations
- Women Health Center, Maccabi Health Services
Arms of the Study
Arm 1
Experimental
GnRH antagomnist hyper-responders
Those defined as hyper-responders will be given recombinant LH.